The Global sphere reconstruction (GSR) - Demonstrating an independent implementation of the astrometric core solution for Gaia

Context. The Gaia ESA mission will estimate the astrometric and physical data of more than one billion objects, providing the largest and most precise catalog of absolute astrometry in the history of Astronomy. The core of this process, the so-called global sphere reconstruction, is represented by the reduction of a subset of these objects which will be used to define the celestial reference frame. As the Hipparcos mission showed, and as is inherent to all kinds of absolute measurements, possible errors in the data reduction can hardly be identified from the catalog, thus potentially introducing systematic errors in all derived work. Aims. Following up on the lessons learned from Hipparcos, our aim is thus to develop an independent sphere reconstruction method that contributes to guarantee the quality of the astrometric results without fully reproducing the main processing chain. Methods. Indeed, given the unfeasibility of a complete replica of the data reduction pipeline, an astrometric verification unit (AVU) was instituted by the Gaia Data Processing and Analysis Consortium (DPAC). One of its jobs is to implement and operate an independent global sphere reconstruction (GSR), parallel to the baseline one (AGIS, namely Astrometric Global Iterative Solution) but limited to the primary stars and for validation purposes, to compare the two results, and to report on any significant differences. Results. Tests performed on simulated data show that GSR is able to reproduce at the sub-$\mu$as level the results of the AGIS demonstration run presented in Lindegren et al. (2012). Conclusions. Further development is ongoing to improve on the treatment of real data and on the software modules that compare the AGIS and GSR solutions to identify possible discrepancies above the tolerance level set by the accuracy of the Gaia catalog.Comment: Accepted for publication on Astronomy & Astrophysic

Preclinical evaluation of EpCAM-binding designed ankyrin repeat proteins (DARPins) as targeting moieties for bimodal near-infrared fluorescence and photoacoustic imaging of cancer

PURPOSE Fluorescence-guided surgery (FGS) can play a key role in improving radical resection rates by assisting surgeons to gain adequate visualization of malignant tissue intraoperatively. Designed ankyrin repeat proteins (DARPins) possess optimal pharmacokinetic and other properties for in vivo imaging. This study aims to evaluate the preclinical potential of epithelial cell adhesion molecule (EpCAM)-binding DARPins as targeting moieties for near-infrared fluorescence (NIRF) and photoacoustic (PA) imaging of cancer. METHODS EpCAM-binding DARPins Ac2, Ec4.1, and non-binding control DARPin Off7 were conjugated to IRDye 800CW and their binding efficacy was evaluated on EpCAM-positive HT-29 and EpCAM-negative COLO-320 human colon cancer cell lines. Thereafter, NIRF and PA imaging of all three conjugates were performed in HT-29_luc2 tumor-bearing mice. At 24 h post-injection, tumors and organs were resected and tracer biodistributions were analyzed. RESULTS Ac2-800CW and Ec4.1-800CW specifically bound to HT-29 cells, but not to COLO-320 cells. Next, 6 nmol and 24 h were established as the optimal in vivo dose and imaging time point for both DARPin tracers. At 24 h post-injection, mean tumor-to-background ratios of 2.60 ± 0.3 and 3.1 ± 0.3 were observed for Ac2-800CW and Ec4.1-800CW, respectively, allowing clear tumor delineation using the clinical Artemis NIRF imager. Biodistribution analyses in non-neoplastic tissue solely showed high fluorescence signal in the liver and kidney, which reflects the clearance of the DARPin tracers. CONCLUSION Our encouraging results show that EpCAM-binding DARPins are a promising class of targeting moieties for pan-carcinoma targeting, providing clear tumor delineation at 24 h post-injection. The work described provides the preclinical foundation for DARPin-based bimodal NIRF/PA imaging of cancer

Recognizing and Resolving Social Dilemmas in Supply Chain Public–Private Partnerships

The public-private partnership is a popular strategy for creating global sustainable value. However, many public-private partnerships struggle to realize their value-added potential. Why do some public-private partnerships succeed while others fail, and how may those struggling succeed? Combining supply-chain integration and social dilemma perspectives into the conversation of public-private partnerships, we examine the dynamics and psychology ofcooperation necessary for public-private partnership success. Addressing the first part of our research question, we recognize three social dilemmas that can manifest while managing public-private partnership supply chains: a give-some dilemma, a take-some dilemma, and a give-or-take-some dilemma. To address the second part of our research question, we present a taxonomy of strategies resolving these public-private partnership social dilemmas through the enhancement of trust, self-efficacy, and/or social responsibility. We discuss implications for public-private partnerships, supply-chain, and social dilemma literatures

Empiema e pneumonia pneumocócica bacterêmica em menores de cinco anos de idade

We compared bacteremic pneumococcal pneumonia (BPP) and pneumococcal empyema (PE), in terms of clinical, radiological, and laboratory findings, in under-fives. A cross-sectional nested cohort study, involving under-fives (102 with PE and 128 with BPP), was conducted at 12 centers in Argentina, Brazil, and the Dominican Republic. Among those with PE, mean age was higher; disease duration was longer; and tachypnea, dyspnea, and high leukocyte counts were more common. Among those with BPP, fever and lethargy were more common. It seems that children with PE can be distinguished from those with BPP on the basis of clinical and laboratory findings. Because both conditions are associated with high rates of morbidity and mortality, prompt diagnosis is crucial.Canadian International Development Agency (CIDA)Pan American Health OrganizationWorld Health Organization Department of Child and Adolescent Health and DevelopmentBoston University Applied Research on Child Health (ARCH) Project (United States Agency for International Development)Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, BrazilUniv Fed Sao Paulo, Paulista Sch Med, Sao Paulo, BrazilPedro Elizalde Childrens Hosp, Buenos Aires, DF, ArgentinaSanta Casa Sch Med Sci Sao Paulo, Dept Pediat, Sao Paulo, BrazilDurand Municipal Hosp, Dept Maternal & Child Hlth, Buenos Aires, DF, ArgentinaUniv Fed Rio de Janeiro, Sch Med, Dept Pediat, Rio De Janeiro, BrazilAdolfo Lutz Inst, Sao Paulo, BrazilUniv Fed Fluminense, Niteroi, RJ, BrazilFernando Figueira Inst Integrat Med, Recife, PE, BrazilDr Robert Reid Cabral Childrens Hosp, Dept Infect Dis, Santo Domingo, Dominican RepWHO, Pan Amer Hlth Org, Washington, DC USAUniv Fed Minas Gerais, Belo Horizonte, MG, BrazilUniv Fed Sao Paulo, Paulista Sch Med, Sao Paulo, BrazilBoston University Applied Research on Child Health (ARCH) Project (United States Agency for International Development): HRN-A-00-960010-00Web of Scienc

Penicillin-resistant pneumococcus and risk of treatment failure in pneumonia

Objective: To determine whether the presence of in vitro penicillin-resistant Streptococcus pneumoniae increases the risk of clinical failure in children hospitalised with severe pneumonia and treated with penicillin/ampicillin. Design: Multicentre, prospective, observational study. Setting: 12 tertiary-care centres in three countries in Latin America. Patients: 240 children aged 3-59 months, hospitalised with severe pneumonia and known in vitro susceptibility of S pneumoniae. Intervention: Patients were treated with intravenous penicillin/ampicillin after collection of blood and, when possible, pleural fluid for culture. The minimal inhibitory concentration (MIC) test was used to determine penicillin susceptibility of the pneumococcal strains isolated. Children were continuously monitored until discharge. Main outcome measures: The primary outcome was treatment failure (using clinical criteria). Results: Overall treatment failure was 21%. After allowing for different potential confounders, there was no evidence of association between treatment failure and in vitro resistance of S pneumoniae to penicillin according to the Clinical Laboratory Standards Institute (CLSI)/National Committee for Clinical Laboratory Standards (NCCLS) interpretative standards ((adj)RR = 1.03; 95%Cl: 0.49-1.90 for resistant S pneumoniae). Conclusions: Intravenous penicillin/ampicillin remains the drug of choice for treating penicillin-resistant pneumococcal pneumonia in areas where the MIC does not exceed 2 mu g/ml